

OMTO, Volume 6

Supplemental Information

**Myxoma Virus Optimizes Cisplatin
for the Treatment of Ovarian Cancer In Vitro
and in a Syngeneic Murine Dissemination Model**


Bernice Nounamo, Jason Liem, Martin Cannon, and Jia Liu

Supplemental Figure legends

Supplemental Figure 1. MYXV complements chemotherapy in a replication-independent manner against primary OC tumor cells. A. MYXV complements cisplatin for improved cytotoxicity. Primary patient ascites-derived OvCa-2a tumor cells were mock-treated or infected with MYXV (wt or *M062R*-null MYXV) at an moi of 10; cisplatin treatment at 5 μ M followed by infection, or cisplatin was given before viral infection. The first treatment (virus or chemotherapy) lasted 48 h, followed by 24 h of growth in fresh medium; cells were then treated with a second treatment (chemotherapy or virus) for another 48 h before cell viability was measured by MTT assay similarly as shown in Figure 3. B. MYXV complements gemcitabine -associated cytotoxicity. The primary OvCa-26 OC cell line was used in this study to test combinatorial effect with gemcitabine at a dose of 10 μ M. The study was conducted similarly to that is described above.


Supplemental Figure 2. Single-agent MYXV used to treat ID8 disseminated tumor-bearing mice at late time point significantly prolongs survival. Mice injected with 6×10^6 tumor cells were treated with corresponding therapy as shown at 16 days post-tumor injection. Kaplan-Meier survival curve is shown along with the treatment schedule. Statistical analysis was carried out with the log-rank (Mantel-Cox) test ($p < 0.0001$) and the Gehan-Breslow-Wilcoxon test ($p < 0.0001$). The median survival time of each treatment group is as following: PBS (n=5) 65 days; Gemcitabine (n=8) 78; Cisplatin (n=8) 90; vMyxGFP (wt) (n=8) 101.5; vMyxM062RKO (n=8) 102.5. * $p < 0.05$ and *** $p < 0.0001$.

Supplemental Figure 1.



Supplemental Figure 2.

Treatment Schedule



Syngeneic ID8 OC model of Peritoneal Carcinomatosis

